Patient 52-year-old African-American female.
Chief Complaint
None; the patient was seen for follow-up of a recent stem cell transplant. The patient denied any major symptoms (eg, bone pain, poor appetite); however, she reported minimal fatigue and poor appetite that had only recently returned to normal.
History of Present Illness
Two years prior to this most recent clinic visit, the patient had presented to the emergency department with flu-like symptoms and was found to have normocytic/normochromic anemia. The work-up that followed included serum (SPE) and urine (UPE) protein electrophoresis, immunofixation electrophoresis (IFE), a bone marrow biopsy and examination, and imaging studies of the axial skeleton. SPE revealed the presence of an M-spike in the gamma-region of the gel at a concentration of 6.4 g/dL. IFE, performed on the patient's serum, demonstrated the presence of an IgG kappa monoclonal immunoglobulin ( Figure 1A) . SPE of a sample from the patient's 24-hour urine collection demonstrated an M-spike, subsequently identified by IFE as IgG kappa. Microscopic examination of the patient's stained bone marrow biopsy demonstrated the presence of aberrant plasma cells constituting 64% of all cells observed in the bone marrow. Imaging studies of her axial skeleton revealed lytic lesions in both humeri and femurs, and in the skull, a compression fracture of the T12 vertebra, and a plasmacytoma in her left-side sixth rib. Laboratory testing revealed normal serum electrolytes, calcium, and creatinine levels. The patient started a prolonged chemotherapeutic regimen that included 3 cycles of vincristine, adriamycin, and dexamethasone (VAD), combination therapy with Thalidomide and Decadron, and Decadron maintenance therapy. Each regimen provided only a short-term reduction in the size of her serum Mspike and in her urine free light chain excretion rate. As a prelude to an autologous stem cell transplant, the patient underwent a repeat bone marrow biopsy, SPE, and UPE. The bone marrow biopsy demonstrated 27% aberrant plasma cells, while the SPE again showed an M-spike consistent with IgG kappa (0.38 g/dL); however, the UPE of a sample from a 24-hour urine collection was negative for any intact or free light chain immunoglobulins (data not shown). The patient underwent stem cell mobilization followed by bone marrow myeloablation using high-dose melphalan therapy and stem cell transfusion. She tolerated the procedure well, requiring only administration of packed red blood cells and platelets to maintain an adequate cell count of these formed elements while engraftment was occurring.
Past Medical History
Hypertension, community-acquired pneumonia, and hip repair with insertion of bilateral intramedullary nails. The patient had no known drug allergies and was currently taking: Bactrim DS (1 tablet po bid every Saturday and Sunday); Acyclovir (400 mg bid); Protonix (40 mg qd); Norvasc (5 mg qd); potassium chloride (20 mEq qd).
Family/Social History
The patient's father died of colon cancer; she had no family history of any hematologic malignancies. She denied use of alcohol, tobacco, or drugs of abuse.
Physical Examination
The patient appeared comfortable and in no acute distress. No abnormal findings were noted on complete physical examination. (Table 1) 4. In 1999, a panel of experts published 9 guidelines for the clinical and laboratory evaluation of patients with monoclonal gammopathies 4 that are summarized in Table 3 .
Principal Laboratory Findings, Post-Stem Cell Transplant

5.
Despite the fact that the patient had no evidence of residual disease on examination of her bone marrow, she continued to have an abnormal serum protein electrophoresis pattern (SPEP). Moreover, the SPEP originally seen on electrophoresis of her serum had changed significantly from a single IgG kappa M-protein to an oligoclonal pattern consisting of IgG kappa, IgG lambda, and free lambda light chains. It is likely that the patient's markedly decreased platelet count and modestly decreased hemoglobin and hematocrit values ( Table 1) were due to continued bone marrow recovery following melphalan therapy and stem cell transplantation.
6. Transient oligoclonal (ie, >2 M-protein bands on SPEP) and monoclonal gammopathies occur in at least 50% of all patients after stem cell transplant and in at least 10% of patients with multiple myeloma treated with stem cell transplant. 3, 6 These bands have been shown to appear between 2 to 6 months post-stem cell transplant and persist on SPEPs for an average of 6 months. 3 
7.
When oligoclonal bands or a monoclonal band with a different immunophenotype than the band observed initially are observed, the differential diagnosis includes a change in M-protein production by the original plasma cell clone, the emergence of a second malignant clone, or the evidence for immune system regeneration following stem cell transplant therapy. To date, most studies favor the latter hypothesis; the bands represent a benign phenomenon associated with the recovery of immune function in patients who have received a stem cell transplant with or without myeloablative bone marrow therapy prior to stem cell transplantation. 3,6-8
8.
One study of patients with multiple myeloma who were treated with stem cell transplantation, with or without prior myeloablation, revealed a significant relationship between the appearance of abnormal protein bands by SPE and IFE after transplantation and a higher likelihood of positive clinical response, event-free survival, and overall survival. 6 9. For more than 2 decades, the standard therapy for patients with symptomatic multiple myeloma has included a wide variety of chemotherapeutic regimens. The most commonly used regimens include combined melphalan and prednisone therapy and the combination of vincristine, adriamycin, and dexamethasone (VAD). 1 Such treatments are associated with a median survival of 2 to 3 years. Other chemotherapeutic regimens, which have been used as both frontline and relapse therapies, include pulse dexamethasone and combined therapy with thalidomide and dexamethasone. 1 Unfortunately, almost all patients who initially respond to chemotherapy eventually relapse. In recent years, high-dose chemotherapy followed by autologous stem cell transplantation has become an important alternative frontline treatment for younger patients (<70 years) as well as a rescue therapy for patients who relapse after chemotherapy. This treatment achieves higher complete response rates compared to chemotherapy alone. Prolonged survival (>6 years), however, remains rare. 9 LM Figure 1B) WBC, white blood cell; SPEP, serum protein electrophoresis pattern; IFE immunofixation electrophoresis CRAB, hypercalc cemia-r renal dysfunction-a anemia-lytic b bone lesions; ULN, upper limit of normal; Hb, hemoglobin; LLN, lower limit of normal.
